Immix Biopharma, Inc. (IMMX)
NASDAQ: IMMX · Real-Time Price · USD
10.14
+0.16 (1.60%)
Jun 29, 2026, 2:17 PM EDT - Market open
Immix Biopharma Employees
As of December 31, 2025, Immix Biopharma had 21 total employees, including 18 full-time and 3 part-time employees. The number of employees did not change compared to the previous year.
Employees
21
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$1,665,846
Market Cap
721.87M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 21 | 0 | - |
| Dec 31, 2024 | 21 | 4 | 23.53% |
| Dec 31, 2023 | 17 | 6 | 54.55% |
| Dec 31, 2022 | 11 | 9 | 450.00% |
| Dec 31, 2021 | 2 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Rigel Pharmaceuticals | 174 |
| Allogene Therapeutics | 152 |
| Inventiva | 77 |
| Aclaris Therapeutics | 73 |
| CytomX Therapeutics | 69 |
| SpyGlass Pharma | 68 |
| Oculis Holding AG | 60 |
| Candel Therapeutics | 55 |
IMMX News
- 11 days ago - Immix Biopharma initiated with a Buy at BofA - TheFly
- 12 days ago - Immix Biopharma initiated with an Outperform at LifeSci Capital - TheFly
- 12 days ago - Immix Biopharma Slides: Corporate presentation - Filings
- 5 weeks ago - Immix Biopharma Announces Closing of $150 Million Underwritten Offering of Common Stock - GlobeNewsWire
- 5 weeks ago - Immix Biopharma price target raised to $20 from $15 at H.C. Wainwright - TheFly
- 5 weeks ago - Immix Biopharma Announces Pricing of $150 Million Underwritten Offering of Common Stock - GlobeNewsWire
- 5 weeks ago - Immix Biopharma’s NXC-201 reaches 95% complete response rate in AL amyloidosis - TheFly
- 5 weeks ago - Immix Biopharma Announces 95% Complete Response Rate in Interim Update From relapsed/refractory AL Amyloidosis Clinical Trial NEXICART-2 - GlobeNewsWire